Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 avr. 2026 08h00 HE | Source: Bladder Cancer Advocacy Network

BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer

Bethesda, MD, April 09, 2026 (GLOBE NEWSWIRE) -- The Bladder Cancer Advocacy Network (BCAN) today announced that Ferring Pharmaceuticals and the Astellas/Pfizer Alliance will serve as National...
09 avr. 2026 08h00 HE | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib...
09 avr. 2026 08h00 HE | Source: Anathapindika Health LLC

The Growing Connection Between Microplastics and the Human Heart

Fort Lauderdale, FL, April 09, 2026 (GLOBE NEWSWIRE) -- The presence of microplastics and nanoplastics (MNPs) in the human heart has been gaining attention in recent years. A study back in 2024...
09 avr. 2026 08h00 HE | Source: Amneal Pharmaceuticals LLC

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and...
09 avr. 2026 08h00 HE | Source: Cerevance, Inc.

Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting

Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trialsMeeting...
09 avr. 2026 07h30 HE | Source: Smith & Nephew UK Ltd

Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*

Results from the first-ever randomized control trial for the REGENETEN Implant in partial-thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today...
09 avr. 2026 07h30 HE | Source: InflaRx N.V.

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
09 avr. 2026 07h30 HE | Source: Kura Oncology, Inc.

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30...
09 avr. 2026 07h00 HE | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical...
09 avr. 2026 07h00 HE | Source: Soleo Health Holdings, Inc.

Soleo Health Opens New Ambulatory Infusion Center in Austin, Texas

FRISCO, Texas and AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of...

Page précédente

Page suivante